Guangdong Zhaotai Cell Biology Technology

Guangdong Zhaotai Cell Biology Technology is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, dedicated to the development of next-generation immune cell therapies. The company utilizes a proprietary fourth-generation CAR-T cell platform to address both hematological cancers and solid tumors, which remain a significant unmet medical need. Its lead programs include therapies targeting CD19 for B-cell malignancies and Glypican-3 (GPC3) for hepatocellular carcinoma. Zhaotai maintains a strong research orientation, often collaborating with the Guangzhou Institutes of Biomedicine and Health (GIBH) under the Chinese Academy of Sciences. The company's manufacturing facilities are designed to meet GMP standards for the production of high-quality cell therapy products. By integrating advanced genetic engineering with clinical research, Zhaotai aims to provide more effective and accessible treatment options for cancer patients.